



# Medical Discovery Partners LLC



**Contact:**  
Steven Bogen MD PhD

**Location:**  
Boston MA

**Email:** [bogen@mdp-partners.com](mailto:bogen@mdp-partners.com)

**Tel:**  
617-636-5422

**Website:**  
<http://mdpcontrols.com>



## Company Profile

**Industry Sector:** Medical Diagnostics/Tissue Diagnostics

**Company Overview:** MDP LLC is commercializing a transformative technology for the medical diagnostic field of Immunohistochemistry (IHC). Unlike other medical diagnostic fields, IHC lacks national standards, calibrators, and assay controls, resulting in widely recognized problems of inaccurate patient test results. MDP has overcome the technical hurdles to solve this problem. The company is located at Tufts Medical Center, Boston MA.

**Target Market(s):** Clinical hospital and independent laboratories



## Key Value Drivers

**Technology:** The first product series is the *IHControls*<sup>TM</sup>, the first system of standardized, reproducible, and quantitative IHC test controls.

**Competitive Advantage:** The competition is homemade test controls that clinical laboratories prepare from leftover, old patient samples. Homemade controls are labor-intensive to prepare, inconsistent over time, of unknown concentration, and non-standardized.

**Plan & Strategy:** MDP will be seeking a strategic partner, an established vendor in the IHC market, for product distribution. Education through publications, seminars, advertising, and word-of-mouth will be important in conveying the advantages of a standardized commercial product where none previously existed.



## Management

**Leadership:** President: Steven Bogen MD PhD

Dr. Bogen is a Board-certified Clinical Pathologist and serial entrepreneur. Previously, he founded and led CytoLogix, a VC-backed company in Cambridge, MA that developed the Artisan<sup>®</sup> instrument, the first of its kind for the histopathology laboratory (now sold through Dako/Agilent Corp). There was a successful exit through both a sale to Dako and receipt of a \$49 MM patent infringement settlement from a 3<sup>rd</sup> party.



## Product Pipeline

**1. Pipeline One:** The *IHControls*<sup>TM</sup> comprise a series of IHC test controls relating to tests for different types of cancers, including test panels for breast cancer, hematologic malignancies, lung and GI cancer, general pathology, etc. The *IHControls*<sup>TM</sup> are in clinical testing.

**2. Pipeline Two:** The *IHCalibrators* will enable for the first time IHC test results with quantitative units of measure. They will be especially important where quantification and accuracy are critical, such as tissue diagnostic tests linked to specific anti-cancer drugs.